

The study entitled “A Phase III, Randomised, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide (16 mg) in Patients Suffering from Polymorphic Light Eruption (PLE)” (CUV026) did not commence recruitment. No results can be presented.